| Description | This product is a human neutralizing antibody binding to middle east respiratory syndrome coronavirus (MERS-CoV) Spike glycoprotein. It interacts with the MERS-CoV B domain. It also exhibits high affinity with EBOV glycoprotein and neutralization efficiency against Ebola virus. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | MERS-CoV |
| Cross Reactivity | England1, EMC/2012, Jordan-N3/2012 |
| Epitope | B domain |
| Neutralization Mechanism | It interacts with the MERS-CoV B domain. |
| Isotype | IgG |
| Expression Species | HEK293F or CHO cell |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | MERS-CoV S |
| Alternative Name | Middle East respiratory syndrome coronavirus spike glycoprotein |
| Research Area | Infectious Disease |
| Related Disease | Respiratory tract infections, Atypical pneumonia |
